McCullough Kristen
26PUBLICATIONS
64CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (26)
Sort by Publication Date:
|Apr 06, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.Saubia Fathima, Lior Rokach, Nour Ghosoun
|Dec 13, 2024
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.Naseema Gangat, Azeem Elbeih, Nour Ghosoun
|Oct 01, 2024
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.Zhuoer Xie, Jenna Fernandez, Terra Lasho
|Apr 02, 2024
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.Marissa Li, Anmol Baranwal, Mark Gurney
|Dec 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.Omer Karrar, Maymona Abdelmagid, Masooma Rana
|Dec 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Naseema Gangat, Omer Karrar, Moazah Iftikhar
Pageof 5
Frequent Collaborators
17 joint publications
Mrinal Patnaik
15 joint publications
Naseema Gangat
14 joint publications
Ayalew Tefferi
12 joint publications
Kebede H Begna
11 joint publications
Mithun Vinod Shah
11 joint publications
Mark R Litzow
10 joint publications
Aref Al-Kali
10 joint publications
Abhishek Mangaonkar
9 joint publications
Talha Badar
6 joint publications
Animesh Pardanani
